Reported Earnings • Jul 15
Second quarter 2022 earnings released: CA$2.13 loss per share (vs CA$0.17 loss in 2Q 2021) Second quarter 2022 results: CA$2.13 loss per share (down from CA$0.17 loss in 2Q 2021). Revenue: CA$24.0m (up 28% from 2Q 2021). Net loss: CA$160.8m (loss widened CA$152.1m from 2Q 2021). Over the next year, revenue is forecast to grow 66%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 16 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Apr 27
Independent Director recently bought €98k worth of stock On the 21st of April, Andrew Cockwell bought around 90k shares on-market at roughly €1.09 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €7.0m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Apr 21
Independent Director recently bought €70k worth of stock On the 19th of April, Guy Beaudin bought around 65k shares on-market at roughly €1.08 per share. In the last 3 months, there was an even bigger purchase from another insider worth €91k. Insiders have collectively bought €6.9m more in shares than they have sold in the last 12 months. Reported Earnings • Apr 15
First quarter 2022 earnings released: CA$0.38 loss per share (vs CA$0.14 loss in 1Q 2021) First quarter 2022 results: CA$0.38 loss per share (down from CA$0.14 loss in 1Q 2021). Revenue: CA$23.2m (up 16% from 1Q 2021). Net loss: CA$25.7m (loss widened 319% from 1Q 2021). Over the next year, revenue is forecast to grow 71%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Recent Insider Transactions • Apr 08
Independent Director recently bought €91k worth of stock On the 5th of April, Andrew Cockwell bought around 47k shares on-market at roughly €1.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €6.7m more in shares than they have sold in the last 12 months. Reported Earnings • Mar 02
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: CA$0.88 loss per share (down from CA$0.49 loss in FY 2020). Revenue: CA$78.2m (down 6.7% from FY 2020). Net loss: CA$49.0m (loss widened 137% from FY 2020). Revenue missed analyst estimates by 3.3%. Over the next year, revenue is forecast to grow 78%, compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings. Recent Insider Transactions • Oct 21
CEO & Chairman recently bought €80k worth of stock On the 18th of October, Andrew Robson bought around 59k shares on-market at roughly €1.35 per share. This was the largest purchase by an insider in the last 3 months. Andrew has been a buyer over the last 12 months, purchasing a net total of €193k worth in shares. Reported Earnings • Oct 14
Third quarter 2021 earnings released: CA$0.076 loss per share (vs CA$0.024 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$21.0m (up 16% from 3Q 2020). Net loss: CA$12.8m (loss widened 318% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Breakeven Date Change • Sep 23
Forecast to breakeven in 2022 The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Recent Insider Transactions • Aug 11
Insider recently sold €75k worth of stock On the 5th of August, Paolo Pero sold around 43k shares on-market at roughly €1.74 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €6.7m more than they sold in the last 12 months. Executive Departure • Jun 01
Independent Director has left the company On the 25th of May, Nitin Kaushal's tenure as Independent Director ended after 2.7 years in the role. As of March 2021, Nitin personally held 60.00k shares (€104k worth at the time). A total of 4 executives have left over the last 12 months. Executive Departure • May 19
Chief Financial Officer has left the company On the 17th of May, Christopher Buysen's tenure as Chief Financial Officer ended after 2.9 years in the role. As of December 2020, Christopher personally held 333.17k shares (€355k worth at the time). A total of 3 executives have left over the last 12 months. Recent Insider Transactions • Oct 30
CEO & Chairman recently bought €66k worth of stock On the 28th of October, Andrew Robson bought around 71k shares on-market at roughly €0.93 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Andrew has been a net seller over the last 12 months, reducing personal holdings by €909k. Is New 90 Day High Low • Oct 29
New 90-day low: €0.92 The company is down 30% from its price of €1.31 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.68 per share. Is New 90 Day High Low • Oct 06
New 90-day low: €0.97 The company is down 35% from its price of €1.50 on 08 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.61 per share. Is New 90 Day High Low • Sep 18
New 90-day low: €1.22 The company is down 25% from its price of €1.63 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.97 per share. 공시 • Jul 07
The Valens Company Inc. to Report Q2, 2020 Results on Jul 15, 2020 The Valens Company Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Jul 15, 2020 